Correction of SMN2 exon 7 splicing by nusinersen, an antisense oligonucleotide (ASO), became the first approved therapy for SMA in 2016 (Singh N. N. et al., 2017). The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.